Dmitry V. Shcheblyakov

Author

Ministry of Health of the Russian Federation ORCID

Also Known As

D V Shcheblyakov, D. V. Shcheblyakov, D.V. Shcheblyakov, DV Shcheblyakov, Dmitriy V. Shcheblyakov, Dmitry Shcheblyakov, Dmitry V Shcheblyakov, Dmitry V. Shcheblyakov, I.B. Esmagambetov

Publications

Citations

H-Index

Concepts

All Affiliations

Ministry of Health of the Russian Federation Sechenov University Gamalei Institute of Epidemiology and Microbiology Lomonosov Moscow State University 27th Central Research Institute of the Ministry of Defence of the Russian Federation

About

Dmitry V. Shcheblyakov is an author at Ministry of Health of the Russian Federation specializing in immunology, medicine, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	3.4K
2	Engineering	3	3	59
3	Biomolecular Engineering	3	3	73
4	Epidemiology	3	3	151
5	Allergy	2	2	63

Dmitry V. Shcheblyakov

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, The Lancet VaccinationVaccine SafetyVaccinologyInterim AnalysisVaccine Development	2021	1.8K
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova, The Lancet VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2020	1.1K
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia Inna V. Dolzhikova, Olga V. Zubkova, Amir I. Tukhvatulin, Human Vaccines & Immunotherapeutics	2017	132
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants Vladimir А. Gushchin, Inna V. Dolzhikova, Andrei E. Siniavin, Vaccines Rbd DomainImmunologyVaccine HesitancyCovid-19Vaccine Target	2021	118
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, The Lancet Regional Health - Europe	2021	71
Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice Svetlana A. Godakova, A. N. Noskov, I. D. Vinogradova, Toxins	2019	70
Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses Amir I. Tukhvatulin, Alina S. Dzharullaeva, Natalia M. Tukhvatulina, PLoS ONE Adaptive Immune SystemInnate Immune SystemImmunologyHumoral ResponseInnate Immunity	2016	43
Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection Amir I. Tukhvatulin, Ilya Gitlin, Dmitry V. Shcheblyakov, Infection and Immunity Microbial PathogensToll-like Receptor 5ImmunologyImmune RegulationInnate Immune System	2013	41
Virus-Vectored Ebola Vaccines Inna V. Dolzhikova, Elisaveta A. Tokarskaya, Alina S. Dzharullaeva, Acta Naturae VaccinationVaccinologyEbola Virus DiseaseMucosal VaccinationVaccine Development	2017	38
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer Anahit Ghochikyan, Alexander Bagaev, Arpine Davtyan, Journal of Translational Medicine	2014	36

Page 1